General Info

Palatin Technologies is a biopharmaceutical research and development company with a focus on developing melanocortin-based therapeutics. Additionally, the company has a pipeline of product opportunities in development. The company s internal research and development capability, anchored by its proprietary MIDAS drug-discovery technology platform, is the core of its new product development program. Palatin s strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize its commercial potential. The company's flagship proprietary product is Bremelanotide, an intranasally administered melanocortin receptor agonist in development for the treatment of both male and female sexual dysfunction. Palatin Technologies has formed a strategic alliance with King Pharmaceuticals to jointly develop and commercialize Bremelanotide. Palatin Technologies maintains its corporate headquarters in Cranbury, N.J.